What it is: A modified fragment of human growth hormone engineered specifically to trigger fat breakdown without the growth-promoting or insulin-affecting properties of full GH.
Research suggests: Preclinical studies showed strong selective fat reduction; Phase 2 human trials were completed and a partial safety record was established.
Best for: Body composition and fat loss researchers
Key thing to know: Received GRAS (Generally Recognized As Safe) status in the US as a food additive, which provides a limited but real human safety reference.
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment corresponding to amino acids 177–191 of the C-terminal region of human growth hormone, with an added N-terminal tyrosine for stability. Researchers at Monash University in Australia designed it to isolate growth hormone's lipolytic (fat-burning) properties while avoiding its growth-promoting and metabolic side effects, particularly IGF-1 elevation and insulin resistance.
AOD-9604 advanced through Phase 1 and Phase 2 clinical trials for obesity. Development was discontinued not for safety reasons but because Phase 2 fat-loss results fell short of the efficacy threshold for Phase 3. Research interest has since shifted toward a potential role in cartilage repair and regeneration, supported by early in-vitro and animal data.
How it works.
In research, the proposed mechanism has several parts.
The GH fragment: Full-length human growth hormone stimulates fat breakdown (lipolysis) through beta-3 adrenergic receptor activation, but it simultaneously elevates IGF-1 and can impair insulin sensitivity, effects that complicate its use as a metabolic therapeutic. AOD-9604 was specifically engineered to retain the lipolytic activity of the hGH C-terminal fragment while decoupling it from the growth-promoting and insulin-disrupting pathways.
Lipolysis: Research suggests AOD-9604 stimulates lipolysis, the release of stored triglycerides from fat cells for fuel, and inhibits lipogenesis (new fat formation) through the beta-3 adrenergic pathway, without activating IGF-1 receptors or insulin signaling. Think of it as extracting one tool from the growth-hormone toolkit — the fat-metabolism function — and using it without GH's broader hormonal effects.
Cartilage research: The cartilage repair research involves a separate observation: AOD-9604 appears to influence proteoglycan synthesis in chondrocytes (cartilage cells), with in vitro data suggesting it may support cartilage matrix maintenance. This mechanism is distinct from its lipolytic activity and represents an emerging area of research independent of the original obesity indication.
What the research shows.
The research evidence breaks down as follows.
Phase 1 safety: AOD-9604 completed Phase 1 trials confirming safety and tolerability, with no significant adverse events and no IGF-1 elevation. Phase 2 trials in obese subjects over 12–24 weeks showed modest fat loss versus placebo. However, the effect size did not reach the regulatory threshold for the obesity indication, and development was discontinued.
Phase 2 data: The Phase 2 human data is a meaningful but qualified evidence base: the compound was tested in humans, was safe and tolerable, and produced some fat loss, but the magnitude was insufficient for its intended regulatory purpose. Extrapolating from these results means acknowledging the primary clinical endpoint was not met at the doses studied.
Cartilage data: Cartilage repair research is at an earlier stage, primarily in vitro and preclinical studies, with no Phase 2 human data yet published for this indication. This emerging research line is scientifically interesting but should be treated as hypothesis-generating rather than clinically established.
Biomarkers to review first.
Metabolic baseline markers are most relevant to the contexts in which AOD-9604 is researched. IGF-1 is included as a monitoring marker to confirm the absence of IGF-1 elevation, a key design feature of this compound.
What it's commonly researched with.
AOD-9604 is most often discussed in the context of metabolic and body composition protocols, sometimes alongside GH secretagogues or GLP-1 receptor agonists that target complementary fat loss pathways. These pairings represent what appears in the research and community literature, not recommendations for use.